06:55 AM EDT, 07/24/2026 (MT Newswires) -- The European Medicines Agency's human medicines committee recommended approval for Johnson & Johnson (JNJ.F) unit Janssen-Cilag International's plaque psoriasis drug Icotyde, or icotrokinra. Icotyde is intended to treat moderate-to-severe plaque psoriasis in patients above 12 years weighing at least 40 kilograms, according to a Friday release. The agency's endorsement is based on the results of four late-stage studies. The EMA will now send the opinion to the European Commission for the adoption of a decision on an EU-wide marketing authorization.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.